Global Antinematode Drugs Market Growth 2026-2032
The global Antinematode Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Antinematodes are a class of drugs used to prevent and treat parasitic infections caused by nematodes (such as roundworms, pinworms, hookworms, whipworms, etc.). Nematodes are round worms that live in humans or animals and can cause various digestive, respiratory, and other systemic diseases. Antinematodes kill or expel the parasites through different mechanisms (such as inhibiting the worm's energy metabolism, destroying its cell structure, or interfering with its nervous system), thereby helping to clear nematode infections from the body.
United States market for Antinematode Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Antinematode Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Antinematode Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Antinematode Drugs players cover GlaxoSmithKline, Sequent Scientific, K.A. Malle Pharmaceuticals, Lasa Supergenerics Limited, Fredun Pharmaceuticals Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Antinematode Drugs Industry Forecast? looks at past sales and reviews total world Antinematode Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Antinematode Drugs sales for 2026 through 2032. With Antinematode Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antinematode Drugs industry.
This Insight Report provides a comprehensive analysis of the global Antinematode Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antinematode Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antinematode Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antinematode Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antinematode Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Antinematode Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Antinematode Drugs market?
What factors are driving Antinematode Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antinematode Drugs market opportunities vary by end market size?
How does Antinematode Drugs break out by Type, by Application?
Antinematodes are a class of drugs used to prevent and treat parasitic infections caused by nematodes (such as roundworms, pinworms, hookworms, whipworms, etc.). Nematodes are round worms that live in humans or animals and can cause various digestive, respiratory, and other systemic diseases. Antinematodes kill or expel the parasites through different mechanisms (such as inhibiting the worm's energy metabolism, destroying its cell structure, or interfering with its nervous system), thereby helping to clear nematode infections from the body.
United States market for Antinematode Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Antinematode Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Antinematode Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Antinematode Drugs players cover GlaxoSmithKline, Sequent Scientific, K.A. Malle Pharmaceuticals, Lasa Supergenerics Limited, Fredun Pharmaceuticals Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Antinematode Drugs Industry Forecast? looks at past sales and reviews total world Antinematode Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Antinematode Drugs sales for 2026 through 2032. With Antinematode Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antinematode Drugs industry.
This Insight Report provides a comprehensive analysis of the global Antinematode Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antinematode Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Antinematode Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antinematode Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antinematode Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Antinematode Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Albendazole
- Mebendazole
- Piperazine
- Pyrantel Pamoate
- Others
- For Veterinary Use
- For Human Use
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GlaxoSmithKline
- Sequent Scientific
- K.A. Malle Pharmaceuticals
- Lasa Supergenerics Limited
- Fredun Pharmaceuticals Ltd
- Salius Pharma
- Johnson & Johnson
- Amneal Pharmaceuticals
- Cadila Pharmaceuticals
- Eipico
- Esteve Pharmaceuticals
- Shanghai Tengrui Pharmaceutical Co., Ltd.
- Shaanxi Hanwang Pharmaceutical Co., Ltd.
- Beijing Taiyang Pharmaceutical Co., Ltd.
- Guilin Nanyao Pharmaceutical Co., Ltd.
- Fujian Dongrui Pharmaceutical Co., Ltd.
- Jiaozuo Furuitang Pharmaceutical Co., Ltd.
- Shaoxing Minsheng Pharmaceutical Co., Ltd.
- Chengdu Hengda Pharmaceutical Co., Ltd.
- China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
- Diao Group Chengdu Pharmaceutical Co., Ltd.
- Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
- Anhui Shengying Pharmaceutical Co., Ltd.
- Sichuan Tiande Pharmaceutical Co., Ltd.
- Hubei Ruihua Pharmaceutical Co., Ltd.
- Zhejiang Anbet Pharmaceutical Co., Ltd.
What is the 10-year outlook for the global Antinematode Drugs market?
What factors are driving Antinematode Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Antinematode Drugs market opportunities vary by end market size?
How does Antinematode Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antinematode Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Antinematode Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Antinematode Drugs by Country/Region, 2021, 2025 & 2032
2.2 Antinematode Drugs Segment by Type
2.2.1 Albendazole
2.2.2 Mebendazole
2.2.3 Piperazine
2.2.4 Pyrantel Pamoate
2.2.5 Others
2.2.6 Antinematode Drugs Sales by Type
2.2.6.1 Global Antinematode Drugs Sales Market Share by Type (2021-2026)
2.2.6.2 Global Antinematode Drugs Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Antinematode Drugs Sale Price by Type (2021-2026)
2.3 Antinematode Drugs Segment by Application
2.3.1 For Veterinary Use
2.3.2 For Human Use
2.3.3 Antinematode Drugs Sales by Application
2.3.3.1 Global Antinematode Drugs Sale Market Share by Application (2021-2026)
2.3.3.2 Global Antinematode Drugs Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Antinematode Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Antinematode Drugs Breakdown Data by Company
3.1.1 Global Antinematode Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Antinematode Drugs Sales Market Share by Company (2021-2026)
3.2 Global Antinematode Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Antinematode Drugs Revenue by Company (2021-2026)
3.2.2 Global Antinematode Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Antinematode Drugs Sale Price by Company
3.4 Key Manufacturers Antinematode Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antinematode Drugs Product Location Distribution
3.4.2 Players Antinematode Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTINEMATODE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Antinematode Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Antinematode Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Antinematode Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Antinematode Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Antinematode Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Antinematode Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antinematode Drugs Sales Growth
4.4 APAC Antinematode Drugs Sales Growth
4.5 Europe Antinematode Drugs Sales Growth
4.6 Middle East & Africa Antinematode Drugs Sales Growth
5 AMERICAS
5.1 Americas Antinematode Drugs Sales by Country
5.1.1 Americas Antinematode Drugs Sales by Country (2021-2026)
5.1.2 Americas Antinematode Drugs Revenue by Country (2021-2026)
5.2 Americas Antinematode Drugs Sales by Type (2021-2026)
5.3 Americas Antinematode Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antinematode Drugs Sales by Region
6.1.1 APAC Antinematode Drugs Sales by Region (2021-2026)
6.1.2 APAC Antinematode Drugs Revenue by Region (2021-2026)
6.2 APAC Antinematode Drugs Sales by Type (2021-2026)
6.3 APAC Antinematode Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antinematode Drugs by Country
7.1.1 Europe Antinematode Drugs Sales by Country (2021-2026)
7.1.2 Europe Antinematode Drugs Revenue by Country (2021-2026)
7.2 Europe Antinematode Drugs Sales by Type (2021-2026)
7.3 Europe Antinematode Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antinematode Drugs by Country
8.1.1 Middle East & Africa Antinematode Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Antinematode Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Antinematode Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Antinematode Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antinematode Drugs
10.3 Manufacturing Process Analysis of Antinematode Drugs
10.4 Industry Chain Structure of Antinematode Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antinematode Drugs Distributors
11.3 Antinematode Drugs Customer
12 WORLD FORECAST REVIEW FOR ANTINEMATODE DRUGS BY GEOGRAPHIC REGION
12.1 Global Antinematode Drugs Market Size Forecast by Region
12.1.1 Global Antinematode Drugs Forecast by Region (2027-2032)
12.1.2 Global Antinematode Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Antinematode Drugs Forecast by Type (2027-2032)
12.7 Global Antinematode Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Antinematode Drugs Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Sequent Scientific
13.2.1 Sequent Scientific Company Information
13.2.2 Sequent Scientific Antinematode Drugs Product Portfolios and Specifications
13.2.3 Sequent Scientific Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sequent Scientific Main Business Overview
13.2.5 Sequent Scientific Latest Developments
13.3 K.A. Malle Pharmaceuticals
13.3.1 K.A. Malle Pharmaceuticals Company Information
13.3.2 K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.3.3 K.A. Malle Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 K.A. Malle Pharmaceuticals Main Business Overview
13.3.5 K.A. Malle Pharmaceuticals Latest Developments
13.4 Lasa Supergenerics Limited
13.4.1 Lasa Supergenerics Limited Company Information
13.4.2 Lasa Supergenerics Limited Antinematode Drugs Product Portfolios and Specifications
13.4.3 Lasa Supergenerics Limited Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Lasa Supergenerics Limited Main Business Overview
13.4.5 Lasa Supergenerics Limited Latest Developments
13.5 Fredun Pharmaceuticals Ltd
13.5.1 Fredun Pharmaceuticals Ltd Company Information
13.5.2 Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolios and Specifications
13.5.3 Fredun Pharmaceuticals Ltd Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Fredun Pharmaceuticals Ltd Main Business Overview
13.5.5 Fredun Pharmaceuticals Ltd Latest Developments
13.6 Salius Pharma
13.6.1 Salius Pharma Company Information
13.6.2 Salius Pharma Antinematode Drugs Product Portfolios and Specifications
13.6.3 Salius Pharma Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Salius Pharma Main Business Overview
13.6.5 Salius Pharma Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Antinematode Drugs Product Portfolios and Specifications
13.7.3 Johnson & Johnson Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Amneal Pharmaceuticals
13.8.1 Amneal Pharmaceuticals Company Information
13.8.2 Amneal Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.8.3 Amneal Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Amneal Pharmaceuticals Main Business Overview
13.8.5 Amneal Pharmaceuticals Latest Developments
13.9 Cadila Pharmaceuticals
13.9.1 Cadila Pharmaceuticals Company Information
13.9.2 Cadila Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.9.3 Cadila Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Cadila Pharmaceuticals Main Business Overview
13.9.5 Cadila Pharmaceuticals Latest Developments
13.10 Eipico
13.10.1 Eipico Company Information
13.10.2 Eipico Antinematode Drugs Product Portfolios and Specifications
13.10.3 Eipico Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Eipico Main Business Overview
13.10.5 Eipico Latest Developments
13.11 Esteve Pharmaceuticals
13.11.1 Esteve Pharmaceuticals Company Information
13.11.2 Esteve Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.11.3 Esteve Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Esteve Pharmaceuticals Main Business Overview
13.11.5 Esteve Pharmaceuticals Latest Developments
13.12 Shanghai Tengrui Pharmaceutical Co., Ltd.
13.12.1 Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information
13.12.2 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.12.3 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Shanghai Tengrui Pharmaceutical Co., Ltd. Main Business Overview
13.12.5 Shanghai Tengrui Pharmaceutical Co., Ltd. Latest Developments
13.13 Shaanxi Hanwang Pharmaceutical Co., Ltd.
13.13.1 Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information
13.13.2 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.13.3 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Shaanxi Hanwang Pharmaceutical Co., Ltd. Main Business Overview
13.13.5 Shaanxi Hanwang Pharmaceutical Co., Ltd. Latest Developments
13.14 Beijing Taiyang Pharmaceutical Co., Ltd.
13.14.1 Beijing Taiyang Pharmaceutical Co., Ltd. Company Information
13.14.2 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.14.3 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beijing Taiyang Pharmaceutical Co., Ltd. Main Business Overview
13.14.5 Beijing Taiyang Pharmaceutical Co., Ltd. Latest Developments
13.15 Guilin Nanyao Pharmaceutical Co., Ltd.
13.15.1 Guilin Nanyao Pharmaceutical Co., Ltd. Company Information
13.15.2 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.15.3 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Guilin Nanyao Pharmaceutical Co., Ltd. Main Business Overview
13.15.5 Guilin Nanyao Pharmaceutical Co., Ltd. Latest Developments
13.16 Fujian Dongrui Pharmaceutical Co., Ltd.
13.16.1 Fujian Dongrui Pharmaceutical Co., Ltd. Company Information
13.16.2 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.16.3 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Fujian Dongrui Pharmaceutical Co., Ltd. Main Business Overview
13.16.5 Fujian Dongrui Pharmaceutical Co., Ltd. Latest Developments
13.17 Jiaozuo Furuitang Pharmaceutical Co., Ltd.
13.17.1 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information
13.17.2 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.17.3 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Main Business Overview
13.17.5 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Latest Developments
13.18 Shaoxing Minsheng Pharmaceutical Co., Ltd.
13.18.1 Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information
13.18.2 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.18.3 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Shaoxing Minsheng Pharmaceutical Co., Ltd. Main Business Overview
13.18.5 Shaoxing Minsheng Pharmaceutical Co., Ltd. Latest Developments
13.19 Chengdu Hengda Pharmaceutical Co., Ltd.
13.19.1 Chengdu Hengda Pharmaceutical Co., Ltd. Company Information
13.19.2 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.19.3 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Chengdu Hengda Pharmaceutical Co., Ltd. Main Business Overview
13.19.5 Chengdu Hengda Pharmaceutical Co., Ltd. Latest Developments
13.20 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
13.20.1 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information
13.20.2 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.20.3 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Main Business Overview
13.20.5 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Latest Developments
13.21 Diao Group Chengdu Pharmaceutical Co., Ltd.
13.21.1 Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information
13.21.2 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.21.3 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Diao Group Chengdu Pharmaceutical Co., Ltd. Main Business Overview
13.21.5 Diao Group Chengdu Pharmaceutical Co., Ltd. Latest Developments
13.22 Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
13.22.1 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information
13.22.2 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.22.3 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Main Business Overview
13.22.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Latest Developments
13.23 Anhui Shengying Pharmaceutical Co., Ltd.
13.23.1 Anhui Shengying Pharmaceutical Co., Ltd. Company Information
13.23.2 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.23.3 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Anhui Shengying Pharmaceutical Co., Ltd. Main Business Overview
13.23.5 Anhui Shengying Pharmaceutical Co., Ltd. Latest Developments
13.24 Sichuan Tiande Pharmaceutical Co., Ltd.
13.24.1 Sichuan Tiande Pharmaceutical Co., Ltd. Company Information
13.24.2 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.24.3 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Sichuan Tiande Pharmaceutical Co., Ltd. Main Business Overview
13.24.5 Sichuan Tiande Pharmaceutical Co., Ltd. Latest Developments
13.25 Hubei Ruihua Pharmaceutical Co., Ltd.
13.25.1 Hubei Ruihua Pharmaceutical Co., Ltd. Company Information
13.25.2 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.25.3 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Hubei Ruihua Pharmaceutical Co., Ltd. Main Business Overview
13.25.5 Hubei Ruihua Pharmaceutical Co., Ltd. Latest Developments
13.26 Zhejiang Anbet Pharmaceutical Co., Ltd.
13.26.1 Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information
13.26.2 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.26.3 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Zhejiang Anbet Pharmaceutical Co., Ltd. Main Business Overview
13.26.5 Zhejiang Anbet Pharmaceutical Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Antinematode Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Antinematode Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Antinematode Drugs by Country/Region, 2021, 2025 & 2032
2.2 Antinematode Drugs Segment by Type
2.2.1 Albendazole
2.2.2 Mebendazole
2.2.3 Piperazine
2.2.4 Pyrantel Pamoate
2.2.5 Others
2.2.6 Antinematode Drugs Sales by Type
2.2.6.1 Global Antinematode Drugs Sales Market Share by Type (2021-2026)
2.2.6.2 Global Antinematode Drugs Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Antinematode Drugs Sale Price by Type (2021-2026)
2.3 Antinematode Drugs Segment by Application
2.3.1 For Veterinary Use
2.3.2 For Human Use
2.3.3 Antinematode Drugs Sales by Application
2.3.3.1 Global Antinematode Drugs Sale Market Share by Application (2021-2026)
2.3.3.2 Global Antinematode Drugs Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Antinematode Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Antinematode Drugs Breakdown Data by Company
3.1.1 Global Antinematode Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Antinematode Drugs Sales Market Share by Company (2021-2026)
3.2 Global Antinematode Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Antinematode Drugs Revenue by Company (2021-2026)
3.2.2 Global Antinematode Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Antinematode Drugs Sale Price by Company
3.4 Key Manufacturers Antinematode Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Antinematode Drugs Product Location Distribution
3.4.2 Players Antinematode Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTINEMATODE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Antinematode Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Antinematode Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Antinematode Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Antinematode Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Antinematode Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Antinematode Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Antinematode Drugs Sales Growth
4.4 APAC Antinematode Drugs Sales Growth
4.5 Europe Antinematode Drugs Sales Growth
4.6 Middle East & Africa Antinematode Drugs Sales Growth
5 AMERICAS
5.1 Americas Antinematode Drugs Sales by Country
5.1.1 Americas Antinematode Drugs Sales by Country (2021-2026)
5.1.2 Americas Antinematode Drugs Revenue by Country (2021-2026)
5.2 Americas Antinematode Drugs Sales by Type (2021-2026)
5.3 Americas Antinematode Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antinematode Drugs Sales by Region
6.1.1 APAC Antinematode Drugs Sales by Region (2021-2026)
6.1.2 APAC Antinematode Drugs Revenue by Region (2021-2026)
6.2 APAC Antinematode Drugs Sales by Type (2021-2026)
6.3 APAC Antinematode Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Antinematode Drugs by Country
7.1.1 Europe Antinematode Drugs Sales by Country (2021-2026)
7.1.2 Europe Antinematode Drugs Revenue by Country (2021-2026)
7.2 Europe Antinematode Drugs Sales by Type (2021-2026)
7.3 Europe Antinematode Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Antinematode Drugs by Country
8.1.1 Middle East & Africa Antinematode Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Antinematode Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Antinematode Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Antinematode Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Antinematode Drugs
10.3 Manufacturing Process Analysis of Antinematode Drugs
10.4 Industry Chain Structure of Antinematode Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Antinematode Drugs Distributors
11.3 Antinematode Drugs Customer
12 WORLD FORECAST REVIEW FOR ANTINEMATODE DRUGS BY GEOGRAPHIC REGION
12.1 Global Antinematode Drugs Market Size Forecast by Region
12.1.1 Global Antinematode Drugs Forecast by Region (2027-2032)
12.1.2 Global Antinematode Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Antinematode Drugs Forecast by Type (2027-2032)
12.7 Global Antinematode Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GlaxoSmithKline
13.1.1 GlaxoSmithKline Company Information
13.1.2 GlaxoSmithKline Antinematode Drugs Product Portfolios and Specifications
13.1.3 GlaxoSmithKline Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GlaxoSmithKline Main Business Overview
13.1.5 GlaxoSmithKline Latest Developments
13.2 Sequent Scientific
13.2.1 Sequent Scientific Company Information
13.2.2 Sequent Scientific Antinematode Drugs Product Portfolios and Specifications
13.2.3 Sequent Scientific Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sequent Scientific Main Business Overview
13.2.5 Sequent Scientific Latest Developments
13.3 K.A. Malle Pharmaceuticals
13.3.1 K.A. Malle Pharmaceuticals Company Information
13.3.2 K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.3.3 K.A. Malle Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 K.A. Malle Pharmaceuticals Main Business Overview
13.3.5 K.A. Malle Pharmaceuticals Latest Developments
13.4 Lasa Supergenerics Limited
13.4.1 Lasa Supergenerics Limited Company Information
13.4.2 Lasa Supergenerics Limited Antinematode Drugs Product Portfolios and Specifications
13.4.3 Lasa Supergenerics Limited Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Lasa Supergenerics Limited Main Business Overview
13.4.5 Lasa Supergenerics Limited Latest Developments
13.5 Fredun Pharmaceuticals Ltd
13.5.1 Fredun Pharmaceuticals Ltd Company Information
13.5.2 Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolios and Specifications
13.5.3 Fredun Pharmaceuticals Ltd Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Fredun Pharmaceuticals Ltd Main Business Overview
13.5.5 Fredun Pharmaceuticals Ltd Latest Developments
13.6 Salius Pharma
13.6.1 Salius Pharma Company Information
13.6.2 Salius Pharma Antinematode Drugs Product Portfolios and Specifications
13.6.3 Salius Pharma Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Salius Pharma Main Business Overview
13.6.5 Salius Pharma Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Antinematode Drugs Product Portfolios and Specifications
13.7.3 Johnson & Johnson Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Amneal Pharmaceuticals
13.8.1 Amneal Pharmaceuticals Company Information
13.8.2 Amneal Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.8.3 Amneal Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Amneal Pharmaceuticals Main Business Overview
13.8.5 Amneal Pharmaceuticals Latest Developments
13.9 Cadila Pharmaceuticals
13.9.1 Cadila Pharmaceuticals Company Information
13.9.2 Cadila Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.9.3 Cadila Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Cadila Pharmaceuticals Main Business Overview
13.9.5 Cadila Pharmaceuticals Latest Developments
13.10 Eipico
13.10.1 Eipico Company Information
13.10.2 Eipico Antinematode Drugs Product Portfolios and Specifications
13.10.3 Eipico Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Eipico Main Business Overview
13.10.5 Eipico Latest Developments
13.11 Esteve Pharmaceuticals
13.11.1 Esteve Pharmaceuticals Company Information
13.11.2 Esteve Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
13.11.3 Esteve Pharmaceuticals Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Esteve Pharmaceuticals Main Business Overview
13.11.5 Esteve Pharmaceuticals Latest Developments
13.12 Shanghai Tengrui Pharmaceutical Co., Ltd.
13.12.1 Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information
13.12.2 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.12.3 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Shanghai Tengrui Pharmaceutical Co., Ltd. Main Business Overview
13.12.5 Shanghai Tengrui Pharmaceutical Co., Ltd. Latest Developments
13.13 Shaanxi Hanwang Pharmaceutical Co., Ltd.
13.13.1 Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information
13.13.2 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.13.3 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Shaanxi Hanwang Pharmaceutical Co., Ltd. Main Business Overview
13.13.5 Shaanxi Hanwang Pharmaceutical Co., Ltd. Latest Developments
13.14 Beijing Taiyang Pharmaceutical Co., Ltd.
13.14.1 Beijing Taiyang Pharmaceutical Co., Ltd. Company Information
13.14.2 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.14.3 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Beijing Taiyang Pharmaceutical Co., Ltd. Main Business Overview
13.14.5 Beijing Taiyang Pharmaceutical Co., Ltd. Latest Developments
13.15 Guilin Nanyao Pharmaceutical Co., Ltd.
13.15.1 Guilin Nanyao Pharmaceutical Co., Ltd. Company Information
13.15.2 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.15.3 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Guilin Nanyao Pharmaceutical Co., Ltd. Main Business Overview
13.15.5 Guilin Nanyao Pharmaceutical Co., Ltd. Latest Developments
13.16 Fujian Dongrui Pharmaceutical Co., Ltd.
13.16.1 Fujian Dongrui Pharmaceutical Co., Ltd. Company Information
13.16.2 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.16.3 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Fujian Dongrui Pharmaceutical Co., Ltd. Main Business Overview
13.16.5 Fujian Dongrui Pharmaceutical Co., Ltd. Latest Developments
13.17 Jiaozuo Furuitang Pharmaceutical Co., Ltd.
13.17.1 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information
13.17.2 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.17.3 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Main Business Overview
13.17.5 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Latest Developments
13.18 Shaoxing Minsheng Pharmaceutical Co., Ltd.
13.18.1 Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information
13.18.2 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.18.3 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Shaoxing Minsheng Pharmaceutical Co., Ltd. Main Business Overview
13.18.5 Shaoxing Minsheng Pharmaceutical Co., Ltd. Latest Developments
13.19 Chengdu Hengda Pharmaceutical Co., Ltd.
13.19.1 Chengdu Hengda Pharmaceutical Co., Ltd. Company Information
13.19.2 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.19.3 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Chengdu Hengda Pharmaceutical Co., Ltd. Main Business Overview
13.19.5 Chengdu Hengda Pharmaceutical Co., Ltd. Latest Developments
13.20 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
13.20.1 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information
13.20.2 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.20.3 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Main Business Overview
13.20.5 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Latest Developments
13.21 Diao Group Chengdu Pharmaceutical Co., Ltd.
13.21.1 Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information
13.21.2 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.21.3 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Diao Group Chengdu Pharmaceutical Co., Ltd. Main Business Overview
13.21.5 Diao Group Chengdu Pharmaceutical Co., Ltd. Latest Developments
13.22 Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
13.22.1 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information
13.22.2 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.22.3 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Main Business Overview
13.22.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Latest Developments
13.23 Anhui Shengying Pharmaceutical Co., Ltd.
13.23.1 Anhui Shengying Pharmaceutical Co., Ltd. Company Information
13.23.2 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.23.3 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Anhui Shengying Pharmaceutical Co., Ltd. Main Business Overview
13.23.5 Anhui Shengying Pharmaceutical Co., Ltd. Latest Developments
13.24 Sichuan Tiande Pharmaceutical Co., Ltd.
13.24.1 Sichuan Tiande Pharmaceutical Co., Ltd. Company Information
13.24.2 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.24.3 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Sichuan Tiande Pharmaceutical Co., Ltd. Main Business Overview
13.24.5 Sichuan Tiande Pharmaceutical Co., Ltd. Latest Developments
13.25 Hubei Ruihua Pharmaceutical Co., Ltd.
13.25.1 Hubei Ruihua Pharmaceutical Co., Ltd. Company Information
13.25.2 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.25.3 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Hubei Ruihua Pharmaceutical Co., Ltd. Main Business Overview
13.25.5 Hubei Ruihua Pharmaceutical Co., Ltd. Latest Developments
13.26 Zhejiang Anbet Pharmaceutical Co., Ltd.
13.26.1 Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information
13.26.2 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
13.26.3 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Zhejiang Anbet Pharmaceutical Co., Ltd. Main Business Overview
13.26.5 Zhejiang Anbet Pharmaceutical Co., Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Antinematode Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Antinematode Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Albendazole
Table 4. Major Players of Mebendazole
Table 5. Major Players of Piperazine
Table 6. Major Players of Pyrantel Pamoate
Table 7. Major Players of Others
Table 8. Global Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 9. Global Antinematode Drugs Sales Market Share by Type (2021-2026)
Table 10. Global Antinematode Drugs Revenue by Type (2021-2026) & ($ million)
Table 11. Global Antinematode Drugs Revenue Market Share by Type (2021-2026)
Table 12. Global Antinematode Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Antinematode Drugs Sale by Application (2021-2026) & (K Units)
Table 14. Global Antinematode Drugs Sale Market Share by Application (2021-2026)
Table 15. Global Antinematode Drugs Revenue by Application (2021-2026) & ($ million)
Table 16. Global Antinematode Drugs Revenue Market Share by Application (2021-2026)
Table 17. Global Antinematode Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Antinematode Drugs Sales by Company (2021-2026) & (K Units)
Table 19. Global Antinematode Drugs Sales Market Share by Company (2021-2026)
Table 20. Global Antinematode Drugs Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Antinematode Drugs Revenue Market Share by Company (2021-2026)
Table 22. Global Antinematode Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Antinematode Drugs Producing Area Distribution and Sales Area
Table 24. Players Antinematode Drugs Products Offered
Table 25. Antinematode Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Antinematode Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Antinematode Drugs Sales Market Share Geographic Region (2021-2026)
Table 30. Global Antinematode Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Antinematode Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Antinematode Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Antinematode Drugs Sales Market Share by Country/Region (2021-2026)
Table 34. Global Antinematode Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Antinematode Drugs Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Antinematode Drugs Sales by Country (2021-2026) & (K Units)
Table 37. Americas Antinematode Drugs Sales Market Share by Country (2021-2026)
Table 38. Americas Antinematode Drugs Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 40. Americas Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 41. APAC Antinematode Drugs Sales by Region (2021-2026) & (K Units)
Table 42. APAC Antinematode Drugs Sales Market Share by Region (2021-2026)
Table 43. APAC Antinematode Drugs Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 45. APAC Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 46. Europe Antinematode Drugs Sales by Country (2021-2026) & (K Units)
Table 47. Europe Antinematode Drugs Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 49. Europe Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Antinematode Drugs Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Antinematode Drugs Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Antinematode Drugs
Table 55. Key Market Challenges & Risks of Antinematode Drugs
Table 56. Key Industry Trends of Antinematode Drugs
Table 57. Antinematode Drugs Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Antinematode Drugs Distributors List
Table 60. Antinematode Drugs Customer List
Table 61. Global Antinematode Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Antinematode Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Antinematode Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Antinematode Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Antinematode Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Antinematode Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Antinematode Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Antinematode Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Antinematode Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Antinematode Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Antinematode Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. GlaxoSmithKline Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 76. GlaxoSmithKline Antinematode Drugs Product Portfolios and Specifications
Table 77. GlaxoSmithKline Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. GlaxoSmithKline Main Business
Table 79. GlaxoSmithKline Latest Developments
Table 80. Sequent Scientific Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Sequent Scientific Antinematode Drugs Product Portfolios and Specifications
Table 82. Sequent Scientific Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Sequent Scientific Main Business
Table 84. Sequent Scientific Latest Developments
Table 85. K.A. Malle Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 87. K.A. Malle Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. K.A. Malle Pharmaceuticals Main Business
Table 89. K.A. Malle Pharmaceuticals Latest Developments
Table 90. Lasa Supergenerics Limited Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Lasa Supergenerics Limited Antinematode Drugs Product Portfolios and Specifications
Table 92. Lasa Supergenerics Limited Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Lasa Supergenerics Limited Main Business
Table 94. Lasa Supergenerics Limited Latest Developments
Table 95. Fredun Pharmaceuticals Ltd Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolios and Specifications
Table 97. Fredun Pharmaceuticals Ltd Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Fredun Pharmaceuticals Ltd Main Business
Table 99. Fredun Pharmaceuticals Ltd Latest Developments
Table 100. Salius Pharma Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Salius Pharma Antinematode Drugs Product Portfolios and Specifications
Table 102. Salius Pharma Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Salius Pharma Main Business
Table 104. Salius Pharma Latest Developments
Table 105. Johnson & Johnson Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Johnson & Johnson Antinematode Drugs Product Portfolios and Specifications
Table 107. Johnson & Johnson Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Johnson & Johnson Main Business
Table 109. Johnson & Johnson Latest Developments
Table 110. Amneal Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Amneal Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 112. Amneal Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Amneal Pharmaceuticals Main Business
Table 114. Amneal Pharmaceuticals Latest Developments
Table 115. Cadila Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Cadila Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 117. Cadila Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Cadila Pharmaceuticals Main Business
Table 119. Cadila Pharmaceuticals Latest Developments
Table 120. Eipico Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Eipico Antinematode Drugs Product Portfolios and Specifications
Table 122. Eipico Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Eipico Main Business
Table 124. Eipico Latest Developments
Table 125. Esteve Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Esteve Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 127. Esteve Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Esteve Pharmaceuticals Main Business
Table 129. Esteve Pharmaceuticals Latest Developments
Table 130. Shanghai Tengrui Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 132. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. Shanghai Tengrui Pharmaceutical Co., Ltd. Main Business
Table 134. Shanghai Tengrui Pharmaceutical Co., Ltd. Latest Developments
Table 135. Shaanxi Hanwang Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 137. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. Shaanxi Hanwang Pharmaceutical Co., Ltd. Main Business
Table 139. Shaanxi Hanwang Pharmaceutical Co., Ltd. Latest Developments
Table 140. Beijing Taiyang Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 142. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Beijing Taiyang Pharmaceutical Co., Ltd. Main Business
Table 144. Beijing Taiyang Pharmaceutical Co., Ltd. Latest Developments
Table 145. Guilin Nanyao Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 147. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. Guilin Nanyao Pharmaceutical Co., Ltd. Main Business
Table 149. Guilin Nanyao Pharmaceutical Co., Ltd. Latest Developments
Table 150. Fujian Dongrui Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 152. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 153. Fujian Dongrui Pharmaceutical Co., Ltd. Main Business
Table 154. Fujian Dongrui Pharmaceutical Co., Ltd. Latest Developments
Table 155. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 156. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 157. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 158. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Main Business
Table 159. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Latest Developments
Table 160. Shaoxing Minsheng Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 161. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 162. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 163. Shaoxing Minsheng Pharmaceutical Co., Ltd. Main Business
Table 164. Shaoxing Minsheng Pharmaceutical Co., Ltd. Latest Developments
Table 165. Chengdu Hengda Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 166. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 167. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 168. Chengdu Hengda Pharmaceutical Co., Ltd. Main Business
Table 169. Chengdu Hengda Pharmaceutical Co., Ltd. Latest Developments
Table 170. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 171. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 172. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 173. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Main Business
Table 174. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Latest Developments
Table 175. Diao Group Chengdu Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 176. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 177. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 178. Diao Group Chengdu Pharmaceutical Co., Ltd. Main Business
Table 179. Diao Group Chengdu Pharmaceutical Co., Ltd. Latest Developments
Table 180. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 181. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 182. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 183. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Main Business
Table 184. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Latest Developments
Table 185. Anhui Shengying Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 186. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 187. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 188. Anhui Shengying Pharmaceutical Co., Ltd. Main Business
Table 189. Anhui Shengying Pharmaceutical Co., Ltd. Latest Developments
Table 190. Sichuan Tiande Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 191. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 192. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 193. Sichuan Tiande Pharmaceutical Co., Ltd. Main Business
Table 194. Sichuan Tiande Pharmaceutical Co., Ltd. Latest Developments
Table 195. Hubei Ruihua Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 196. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 197. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 198. Hubei Ruihua Pharmaceutical Co., Ltd. Main Business
Table 199. Hubei Ruihua Pharmaceutical Co., Ltd. Latest Developments
Table 200. Zhejiang Anbet Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 201. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 202. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 203. Zhejiang Anbet Pharmaceutical Co., Ltd. Main Business
Table 204. Zhejiang Anbet Pharmaceutical Co., Ltd. Latest Developments
Table 1. Antinematode Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Antinematode Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Albendazole
Table 4. Major Players of Mebendazole
Table 5. Major Players of Piperazine
Table 6. Major Players of Pyrantel Pamoate
Table 7. Major Players of Others
Table 8. Global Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 9. Global Antinematode Drugs Sales Market Share by Type (2021-2026)
Table 10. Global Antinematode Drugs Revenue by Type (2021-2026) & ($ million)
Table 11. Global Antinematode Drugs Revenue Market Share by Type (2021-2026)
Table 12. Global Antinematode Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Antinematode Drugs Sale by Application (2021-2026) & (K Units)
Table 14. Global Antinematode Drugs Sale Market Share by Application (2021-2026)
Table 15. Global Antinematode Drugs Revenue by Application (2021-2026) & ($ million)
Table 16. Global Antinematode Drugs Revenue Market Share by Application (2021-2026)
Table 17. Global Antinematode Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Antinematode Drugs Sales by Company (2021-2026) & (K Units)
Table 19. Global Antinematode Drugs Sales Market Share by Company (2021-2026)
Table 20. Global Antinematode Drugs Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Antinematode Drugs Revenue Market Share by Company (2021-2026)
Table 22. Global Antinematode Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Antinematode Drugs Producing Area Distribution and Sales Area
Table 24. Players Antinematode Drugs Products Offered
Table 25. Antinematode Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Antinematode Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Antinematode Drugs Sales Market Share Geographic Region (2021-2026)
Table 30. Global Antinematode Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Antinematode Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Antinematode Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Antinematode Drugs Sales Market Share by Country/Region (2021-2026)
Table 34. Global Antinematode Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Antinematode Drugs Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Antinematode Drugs Sales by Country (2021-2026) & (K Units)
Table 37. Americas Antinematode Drugs Sales Market Share by Country (2021-2026)
Table 38. Americas Antinematode Drugs Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 40. Americas Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 41. APAC Antinematode Drugs Sales by Region (2021-2026) & (K Units)
Table 42. APAC Antinematode Drugs Sales Market Share by Region (2021-2026)
Table 43. APAC Antinematode Drugs Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 45. APAC Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 46. Europe Antinematode Drugs Sales by Country (2021-2026) & (K Units)
Table 47. Europe Antinematode Drugs Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 49. Europe Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Antinematode Drugs Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Antinematode Drugs Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Antinematode Drugs Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Antinematode Drugs Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Antinematode Drugs
Table 55. Key Market Challenges & Risks of Antinematode Drugs
Table 56. Key Industry Trends of Antinematode Drugs
Table 57. Antinematode Drugs Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Antinematode Drugs Distributors List
Table 60. Antinematode Drugs Customer List
Table 61. Global Antinematode Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Antinematode Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Antinematode Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Antinematode Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Antinematode Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Antinematode Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Antinematode Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Antinematode Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Antinematode Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Antinematode Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Antinematode Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. GlaxoSmithKline Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 76. GlaxoSmithKline Antinematode Drugs Product Portfolios and Specifications
Table 77. GlaxoSmithKline Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. GlaxoSmithKline Main Business
Table 79. GlaxoSmithKline Latest Developments
Table 80. Sequent Scientific Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Sequent Scientific Antinematode Drugs Product Portfolios and Specifications
Table 82. Sequent Scientific Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Sequent Scientific Main Business
Table 84. Sequent Scientific Latest Developments
Table 85. K.A. Malle Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 87. K.A. Malle Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. K.A. Malle Pharmaceuticals Main Business
Table 89. K.A. Malle Pharmaceuticals Latest Developments
Table 90. Lasa Supergenerics Limited Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Lasa Supergenerics Limited Antinematode Drugs Product Portfolios and Specifications
Table 92. Lasa Supergenerics Limited Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Lasa Supergenerics Limited Main Business
Table 94. Lasa Supergenerics Limited Latest Developments
Table 95. Fredun Pharmaceuticals Ltd Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolios and Specifications
Table 97. Fredun Pharmaceuticals Ltd Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Fredun Pharmaceuticals Ltd Main Business
Table 99. Fredun Pharmaceuticals Ltd Latest Developments
Table 100. Salius Pharma Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Salius Pharma Antinematode Drugs Product Portfolios and Specifications
Table 102. Salius Pharma Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Salius Pharma Main Business
Table 104. Salius Pharma Latest Developments
Table 105. Johnson & Johnson Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Johnson & Johnson Antinematode Drugs Product Portfolios and Specifications
Table 107. Johnson & Johnson Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Johnson & Johnson Main Business
Table 109. Johnson & Johnson Latest Developments
Table 110. Amneal Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Amneal Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 112. Amneal Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Amneal Pharmaceuticals Main Business
Table 114. Amneal Pharmaceuticals Latest Developments
Table 115. Cadila Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Cadila Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 117. Cadila Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Cadila Pharmaceuticals Main Business
Table 119. Cadila Pharmaceuticals Latest Developments
Table 120. Eipico Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Eipico Antinematode Drugs Product Portfolios and Specifications
Table 122. Eipico Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. Eipico Main Business
Table 124. Eipico Latest Developments
Table 125. Esteve Pharmaceuticals Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. Esteve Pharmaceuticals Antinematode Drugs Product Portfolios and Specifications
Table 127. Esteve Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Esteve Pharmaceuticals Main Business
Table 129. Esteve Pharmaceuticals Latest Developments
Table 130. Shanghai Tengrui Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 132. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 133. Shanghai Tengrui Pharmaceutical Co., Ltd. Main Business
Table 134. Shanghai Tengrui Pharmaceutical Co., Ltd. Latest Developments
Table 135. Shaanxi Hanwang Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 137. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 138. Shaanxi Hanwang Pharmaceutical Co., Ltd. Main Business
Table 139. Shaanxi Hanwang Pharmaceutical Co., Ltd. Latest Developments
Table 140. Beijing Taiyang Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 142. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 143. Beijing Taiyang Pharmaceutical Co., Ltd. Main Business
Table 144. Beijing Taiyang Pharmaceutical Co., Ltd. Latest Developments
Table 145. Guilin Nanyao Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 146. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 147. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 148. Guilin Nanyao Pharmaceutical Co., Ltd. Main Business
Table 149. Guilin Nanyao Pharmaceutical Co., Ltd. Latest Developments
Table 150. Fujian Dongrui Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 151. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 152. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 153. Fujian Dongrui Pharmaceutical Co., Ltd. Main Business
Table 154. Fujian Dongrui Pharmaceutical Co., Ltd. Latest Developments
Table 155. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 156. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 157. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 158. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Main Business
Table 159. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Latest Developments
Table 160. Shaoxing Minsheng Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 161. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 162. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 163. Shaoxing Minsheng Pharmaceutical Co., Ltd. Main Business
Table 164. Shaoxing Minsheng Pharmaceutical Co., Ltd. Latest Developments
Table 165. Chengdu Hengda Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 166. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 167. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 168. Chengdu Hengda Pharmaceutical Co., Ltd. Main Business
Table 169. Chengdu Hengda Pharmaceutical Co., Ltd. Latest Developments
Table 170. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 171. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 172. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 173. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Main Business
Table 174. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Latest Developments
Table 175. Diao Group Chengdu Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 176. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 177. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 178. Diao Group Chengdu Pharmaceutical Co., Ltd. Main Business
Table 179. Diao Group Chengdu Pharmaceutical Co., Ltd. Latest Developments
Table 180. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 181. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 182. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 183. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Main Business
Table 184. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Latest Developments
Table 185. Anhui Shengying Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 186. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 187. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 188. Anhui Shengying Pharmaceutical Co., Ltd. Main Business
Table 189. Anhui Shengying Pharmaceutical Co., Ltd. Latest Developments
Table 190. Sichuan Tiande Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 191. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 192. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 193. Sichuan Tiande Pharmaceutical Co., Ltd. Main Business
Table 194. Sichuan Tiande Pharmaceutical Co., Ltd. Latest Developments
Table 195. Hubei Ruihua Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 196. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 197. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 198. Hubei Ruihua Pharmaceutical Co., Ltd. Main Business
Table 199. Hubei Ruihua Pharmaceutical Co., Ltd. Latest Developments
Table 200. Zhejiang Anbet Pharmaceutical Co., Ltd. Basic Information, Antinematode Drugs Manufacturing Base, Sales Area and Its Competitors
Table 201. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolios and Specifications
Table 202. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 203. Zhejiang Anbet Pharmaceutical Co., Ltd. Main Business
Table 204. Zhejiang Anbet Pharmaceutical Co., Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Antinematode Drugs
Figure 2. Antinematode Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antinematode Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Antinematode Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Antinematode Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Antinematode Drugs Sales Market Share by Country/Region (2025)
Figure 10. Antinematode Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Albendazole
Figure 12. Product Picture of Mebendazole
Figure 13. Product Picture of Piperazine
Figure 14. Product Picture of Pyrantel Pamoate
Figure 15. Product Picture of Others
Figure 16. Global Antinematode Drugs Sales Market Share by Type in 2026
Figure 17. Global Antinematode Drugs Revenue Market Share by Type (2021-2026)
Figure 18. Antinematode Drugs Consumed in For Veterinary Use
Figure 19. Global Antinematode Drugs Market: For Veterinary Use (2021-2026) & (K Units)
Figure 20. Antinematode Drugs Consumed in For Human Use
Figure 21. Global Antinematode Drugs Market: For Human Use (2021-2026) & (K Units)
Figure 22. Global Antinematode Drugs Sale Market Share by Application (2025)
Figure 23. Global Antinematode Drugs Revenue Market Share by Application in 2026
Figure 24. Antinematode Drugs Sales by Company in 2026 (K Units)
Figure 25. Global Antinematode Drugs Sales Market Share by Company in 2026
Figure 26. Antinematode Drugs Revenue by Company in 2026 ($ millions)
Figure 27. Global Antinematode Drugs Revenue Market Share by Company in 2026
Figure 28. Global Antinematode Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Antinematode Drugs Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Antinematode Drugs Sales 2021-2026 (K Units)
Figure 31. Americas Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 32. APAC Antinematode Drugs Sales 2021-2026 (K Units)
Figure 33. APAC Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 34. Europe Antinematode Drugs Sales 2021-2026 (K Units)
Figure 35. Europe Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Antinematode Drugs Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 38. Americas Antinematode Drugs Sales Market Share by Country in 2026
Figure 39. Americas Antinematode Drugs Revenue Market Share by Country (2021-2026)
Figure 40. Americas Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 41. Americas Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 42. United States Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Antinematode Drugs Sales Market Share by Region in 2026
Figure 47. APAC Antinematode Drugs Revenue Market Share by Region (2021-2026)
Figure 48. APAC Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 49. APAC Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 50. China Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. India Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Antinematode Drugs Sales Market Share by Country in 2026
Figure 58. Europe Antinematode Drugs Revenue Market Share by Country (2021-2026)
Figure 59. Europe Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 60. Europe Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 61. Germany Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. France Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Antinematode Drugs Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 69. Egypt Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Antinematode Drugs in 2026
Figure 75. Manufacturing Process Analysis of Antinematode Drugs
Figure 76. Industry Chain Structure of Antinematode Drugs
Figure 77. Channels of Distribution
Figure 78. Global Antinematode Drugs Sales Market Forecast by Region (2027-2032)
Figure 79. Global Antinematode Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Antinematode Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Antinematode Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Antinematode Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Antinematode Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Antinematode Drugs
Figure 2. Antinematode Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Antinematode Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Antinematode Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Antinematode Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Antinematode Drugs Sales Market Share by Country/Region (2025)
Figure 10. Antinematode Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Albendazole
Figure 12. Product Picture of Mebendazole
Figure 13. Product Picture of Piperazine
Figure 14. Product Picture of Pyrantel Pamoate
Figure 15. Product Picture of Others
Figure 16. Global Antinematode Drugs Sales Market Share by Type in 2026
Figure 17. Global Antinematode Drugs Revenue Market Share by Type (2021-2026)
Figure 18. Antinematode Drugs Consumed in For Veterinary Use
Figure 19. Global Antinematode Drugs Market: For Veterinary Use (2021-2026) & (K Units)
Figure 20. Antinematode Drugs Consumed in For Human Use
Figure 21. Global Antinematode Drugs Market: For Human Use (2021-2026) & (K Units)
Figure 22. Global Antinematode Drugs Sale Market Share by Application (2025)
Figure 23. Global Antinematode Drugs Revenue Market Share by Application in 2026
Figure 24. Antinematode Drugs Sales by Company in 2026 (K Units)
Figure 25. Global Antinematode Drugs Sales Market Share by Company in 2026
Figure 26. Antinematode Drugs Revenue by Company in 2026 ($ millions)
Figure 27. Global Antinematode Drugs Revenue Market Share by Company in 2026
Figure 28. Global Antinematode Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Antinematode Drugs Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Antinematode Drugs Sales 2021-2026 (K Units)
Figure 31. Americas Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 32. APAC Antinematode Drugs Sales 2021-2026 (K Units)
Figure 33. APAC Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 34. Europe Antinematode Drugs Sales 2021-2026 (K Units)
Figure 35. Europe Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Antinematode Drugs Sales 2021-2026 (K Units)
Figure 37. Middle East & Africa Antinematode Drugs Revenue 2021-2026 ($ millions)
Figure 38. Americas Antinematode Drugs Sales Market Share by Country in 2026
Figure 39. Americas Antinematode Drugs Revenue Market Share by Country (2021-2026)
Figure 40. Americas Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 41. Americas Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 42. United States Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Antinematode Drugs Sales Market Share by Region in 2026
Figure 47. APAC Antinematode Drugs Revenue Market Share by Region (2021-2026)
Figure 48. APAC Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 49. APAC Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 50. China Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. India Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Antinematode Drugs Sales Market Share by Country in 2026
Figure 58. Europe Antinematode Drugs Revenue Market Share by Country (2021-2026)
Figure 59. Europe Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 60. Europe Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 61. Germany Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. France Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Antinematode Drugs Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Antinematode Drugs Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Antinematode Drugs Sales Market Share by Application (2021-2026)
Figure 69. Egypt Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Antinematode Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Antinematode Drugs in 2026
Figure 75. Manufacturing Process Analysis of Antinematode Drugs
Figure 76. Industry Chain Structure of Antinematode Drugs
Figure 77. Channels of Distribution
Figure 78. Global Antinematode Drugs Sales Market Forecast by Region (2027-2032)
Figure 79. Global Antinematode Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Antinematode Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Antinematode Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Antinematode Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Antinematode Drugs Revenue Market Share Forecast by Application (2027-2032)
